This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Farsang, C. Articles by Kunos, G. Search for Related Content PubMed PubMed Citation Articles by Farsang, C. Articles by Kunos, G.

Circulation, Vol 69, 461-467, Copyright © 1984 by American Heart Association

ARTICLES

Reversal by naloxone of the antihypertensive action of clonidine: involvement of the sympathetic nervous system

C Farsang, J Kapocsi, L Vajda, K Varga, Z Malisak, M Fekete and G Kunos

The effects of clonidine, naloxone, and their combination on arterial blood pressure (BP), heart rate (HR), and hemodynamic and biochemical parameters were examined in 29 patients with essential hypertension. Treatment for 3 days with 0.3 mg/day clonidine reduced BP and HR, and these effects were quickly reversed by a single injection of 0.4 mg iv naloxone in 17 of the patients (responders), but not in the remaining 12 (nonresponders). Responders had higher control values for cardiac output, stroke index, plasma renin activity (PRA), and plasma epinephrine levels than did nonresponders. Basal BP was similar in the two groups, but clonidine decreased BP, PRA, and plasma epinephrine more in responders than in nonresponders. Naloxone given during placebo treatment had no significant effects. During clonidine treatment naloxone increased BP, HR, total peripheral resistance, PRA, and plasma epinephrine and norepinephrine, and decreased stroke volume in responders, whereas in nonresponders its only effect was a small increase in HR. It is concluded that in a subset of hyperadrenergic, hypertensive patients the antihypertensive effect of clonidine involves a naloxone-reversible inhibition of central sympathetic outflow, probably mediated by the release of an endogenous opioid.

This article has been cited by other articles:

				S. Ghione Hypertension-Associated Hypalgesia: Evidence in Experimental Animals and Humans, Pathophysiological Mechanisms, and Potential Clinical Consequences Hypertension, September 1, 1996; 28(3): 494 - 504. [Abstract] [Full Text]